ESMO GU Cancers Spotlight

New findings reveal that GDF-15 neutralization with visugromab and nivolumab significantly enhances long-term responses in advanced cancer patients.

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

A phase 1b/2 trial shows triplet therapy for advanced renal cell carcinoma is feasible but lacks significant response improvement over standard treatment.

Avelumab shows modest, durable responses in advanced penile cancer, highlighting the need for innovative treatments in this challenging patient population.

A phase 2 trial reveals single-dose carboplatin plus radiotherapy offers exceptional long-term survival and minimal toxicity for stage IIa/b seminoma patients.

New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases.

A groundbreaking study reveals that less frequent dosing of pasritamig enhances immune response in advanced prostate cancer, challenging traditional treatment assumptions.

Recent trials at ESMO Congress 2025 clarify treatment options for metastatic renal cell carcinoma, highlighting promising combinations and emerging therapies.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.

A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.

Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Combination therapy with datopotamab deruxtecan and rilvegostomig shows significant antitumor activity in advanced urothelial cancer patients.

A phase 2 study reveals lenvatinib and everolimus significantly improve progression-free survival in metastatic clear cell RCC compared to cabozantinib.

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

The OPTIC RCC trial reveals promising outcomes for patients with angiogenic tumors treated with cabozantinib and nivolumab, showcasing high response rates and tumor reduction.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.